Table 3.
MGG for CML in the epidermis and reticular dermis and antiglycation activity
| MG-induced glycation for CML |
||||
|---|---|---|---|---|
| MG | MGG AQ-CARN | MGG FC-CARN | ||
| Epidermis | Mean | 26.6 | 9.6 | −13.3 |
| SD | 8.8 | 6.4 | 19.0 | |
| Antiglycation activity (% variation vs. MG) | −64 | −150 | ||
| p vs. MG | 0.0006 | 0.0002 | ||
| Reticular dermis | Mean | 34.8 | 20.6 | −7.8 |
| SD | 14.0 | 7.6 | 1.9 | |
| Antiglycation activity (% variation vs. MG) | −41 | −122 | ||
| p vs. MG | 0.0264* | 0.0000** | ||
*
p < 0.05
**
p < 0.01.
MG, methylglyoxal; MGG, MG-induced glycation; AQ-CARN, aqueous solution; FC-CARN, facial cream containing carnosine; ns, non-significant.